Evidence map›Paper›PMID 29931503›Full record

ReviewJournal of molecular neuroscience : MN2019

Effects of PACAP on Dry Eye Symptoms, and Possible Use for Therapeutic Application.

Seiji Shioda, Fumiko Takenoya, Takahiro Hirabayashi, Nobuhiro Wada, Tamotsu Seki, Naoko Nonaka, Tomoya Nakamachi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of molecular neuroscience : MN, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Ocular Surface Ion Transport and Dry Eye Disease.Current ophthalmology reports · 2022
    Article
  6. Review
  7. Article
  8. Review
  9. Stability Test of PACAP in Eye Drops.Journal of molecular neuroscience : MN · 2021
    Article
  10. Protective Effects of PACAP in Peripheral Organs.Frontiers in endocrinology · 2020
    Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Seiji ShiodaGlobal Research Center for Innovative Life Science, Hoshi University School of Pharmacy and Pharmaceutical Sciences, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan. shioda@hoshi.ac.jp.ORCID http://orcid.org/0000-0002-4164-6743
Fumiko TakenoyaGlobal Research Center for Innovative Life Science, Hoshi University School of Pharmacy and Pharmaceutical Sciences, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan.
Takahiro HirabayashiGlobal Research Center for Innovative Life Science, Hoshi University School of Pharmacy and Pharmaceutical Sciences, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan.
Nobuhiro WadaGlobal Research Center for Innovative Life Science, Hoshi University School of Pharmacy and Pharmaceutical Sciences, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan.
Tamotsu SekiDepartment of Anatomy and Ophthalmology, Showa University School of Medicine, Shinagawa-Ku, Tokyo, 142-8555, Japan.
Naoko NonakaDepartment of Oral Anatomy and Developmental Biology, Showa University School of Dentistry, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
Tomoya NakamachiLaboratory of Regulatory Biology, Graduate School of Science and Engineering, University of Toyama, 3190 Gofuku, Toyama, 930-8555, Japan.
Hoshi University · JPShowa University · JPUniversity of Toyama · JP

Funding

Japan Society for the Promotion of Science 2459280, 2459268, 23249079, 15K15670, 16H02684 and 15H01288
6 · The paper itself

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a 27- or 38-amino acid neuropeptide, which belongs to the vasoactive intestinal polypeptide/glucagon/secretin family of peptides. PACAP and its three receptor subtypes are expressed in neural tissues and in the eye, including the retina, cornea, and lacrimal gland. PACAP is known to exert pleiotropic effects on the central nervous system and in eye tissues where it plays important roles in protecting against dry eye. This review provides an overview of current knowledge regarding dry eye symptoms in aged animals and humans and the protective effects, mechanisms of action. In addition, we also refer to the development of a new preventive/therapeutic method by PACAP of dry eye patients.

Indexed as

AnimalsDry Eye SyndromesHumansNeuroprotective AgentsPituitary Adenylate Cyclase-Activating PolypeptideNeuroprotective AgentsPituitary Adenylate Cyclase-Activating PolypeptideAgingDry eyeNeuroprotective functionPACAP

Identifiers

PMID29931503
OpenAlexW2809502524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.